Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donaperminogene seltoplasmid - Helixmith

Drug Profile

Donaperminogene seltoplasmid - Helixmith

Alternative Names: Donaperminogene seltoplasmid; Hepatocyte growth factor gene therapy-Helixmith; Modified hepatocyte growth factor gene therapy-Helixmith; NL003; pCK-HGF-X7; VM-202; VM202-ALS; VM202-CAD; VM202-DPN; VM202-PAD; VM202-Stent; VM202RY

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViroMed Co Ltd
  • Developer Beijing Northland Biotech; Helixmith; Reyon Pharmaceutical
  • Class Anti-ischaemics; Gene therapies; Neuroprotectants; Vascular disorder therapies
  • Mechanism of Action Hepatocyte growth factor expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diabetic foot ulcer; Diabetic neuropathies
  • Phase II Myocardial infarction; Peripheral arterial disorders
  • Phase I/II Amyotrophic lateral sclerosis
  • Phase I Ischaemic heart disorders; Myocardial ischaemia

Most Recent Events

  • 07 Oct 2019 Efficacy, pharmacodynamics and safety data from a phase III extension trial in Diabetic peripheral neuropathy released by Helixmith
  • 23 Sep 2019 Helixmith plans to meet with the US FDA to share details of the results from phase III study in Diabetes neuropathies in December 2019
  • 23 Sep 2019 Efficacy, pharmacokinetic and safety data from a phase III trial in Diabetic peripheral neuropathy released by ViroMed Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top